These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 19965645)
1. SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations. Nowak D; Ogawa S; Müschen M; Kato M; Kawamata N; Meixel A; Nowak V; Kim HS; Kang S; Paquette R; Chang MS; Thoennissen NH; Mossner M; Hofmann WK; Kohlmann A; Weiss T; Haferlach T; Haferlach C; Koeffler HP Blood; 2010 Feb; 115(5):1049-53. PubMed ID: 19965645 [TBL] [Abstract][Full Text] [Related]
2. Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors. Marcé S; Zamora L; Cabezón M; Xicoy B; Boqué C; Fernández C; Grau J; Navarro JT; Fernández de Sevilla A; Ribera JM; Feliu E; Millá F; Med Clin (Barc); 2013 Aug; 141(3):95-9. PubMed ID: 23433665 [TBL] [Abstract][Full Text] [Related]
3. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients. Wongboonma W; Thongnoppakhun W; Auewarakul CU Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255 [TBL] [Abstract][Full Text] [Related]
4. Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors. Kim WS; Kim D; Kim DW; Kweon IY; Kim SH; Goh HG; Park SH; Lee J Hematol Oncol; 2010 Jun; 28(2):82-8. PubMed ID: 19768693 [TBL] [Abstract][Full Text] [Related]
5. BCR-ABL mutational studies for predicting the response of patients with chronic myeloid leukaemia to second-generation tyrosine kinase inhibitors after imatinib failure. Kwan TK; Ma ES; Chan YY; Wan TS; Liu HS; Sim JP; Yeung YM; Lie AK; Yip SF Hong Kong Med J; 2009 Oct; 15(5):365-73. PubMed ID: 19801694 [TBL] [Abstract][Full Text] [Related]
10. Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy. Parker WT; Lawrence RM; Ho M; Irwin DL; Scott HS; Hughes TP; Branford S J Clin Oncol; 2011 Nov; 29(32):4250-9. PubMed ID: 21990409 [TBL] [Abstract][Full Text] [Related]
11. Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia. Kim TD; Türkmen S; Schwarz M; Koca G; Nogai H; Bommer C; Dörken B; Daniel P; le Coutre P Haematologica; 2010 Apr; 95(4):582-8. PubMed ID: 20015884 [TBL] [Abstract][Full Text] [Related]
12. Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity. Härtel N; Klag T; Hanfstein B; Mueller MC; Schenk T; Erben P; Hochhaus A; La Rosée P J Cancer Res Clin Oncol; 2012 Feb; 138(2):203-12. PubMed ID: 22089930 [TBL] [Abstract][Full Text] [Related]
13. Overcoming kinase resistance in chronic myeloid leukemia. Lee F; Fandi A; Voi M Int J Biochem Cell Biol; 2008; 40(3):334-43. PubMed ID: 18401881 [TBL] [Abstract][Full Text] [Related]
14. Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia. Verma D; Fava C; Kantarjian H; Cortes J Am J Hematol; 2009 Apr; 84(4):256-7. PubMed ID: 19260121 [No Abstract] [Full Text] [Related]
15. A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib. Ernst T; Gruber FX; Pelz-Ackermann O; Maier J; Pfirrmann M; Müller MC; Mikkola I; Porkka K; Niederwieser D; Hochhaus A; Lange T Haematologica; 2009 Sep; 94(9):1227-35. PubMed ID: 19608684 [TBL] [Abstract][Full Text] [Related]
16. Ever-advancing chronic myeloid leukemia treatment. Kimura S; Ando T; Kojima K Int J Clin Oncol; 2014 Feb; 19(1):3-9. PubMed ID: 24258348 [TBL] [Abstract][Full Text] [Related]
17. Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. Soverini S; Gnani A; Colarossi S; Castagnetti F; Abruzzese E; Paolini S; Merante S; Orlandi E; de Matteis S; Gozzini A; Iacobucci I; Palandri F; Gugliotta G; Papayannidis C; Poerio A; Amabile M; Cilloni D; Rosti G; Baccarani M; Martinelli G Blood; 2009 Sep; 114(10):2168-71. PubMed ID: 19589924 [TBL] [Abstract][Full Text] [Related]
18. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy. Ferri C; Bianchini M; Bengió R; Larripa I Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144 [TBL] [Abstract][Full Text] [Related]